156 related articles for article (PubMed ID: 19544690)
1. The pathway ahead in melanoma trials.
Miller AJ; Markovic SN; Haluska P
Oncology (Williston Park); 2009 May; 23(6):496, 498, 500. PubMed ID: 19544690
[No Abstract] [Full Text] [Related]
2. Progression of NRAS and BRAF mutations in cutaneous melanoma.
Rosso R; Romagosa Y; Kirsner RS
J Invest Dermatol; 2009 Jun; 129(6):1318. PubMed ID: 19434085
[No Abstract] [Full Text] [Related]
3. Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations.
Jovanovic B; Egyhazi S; Eskandarpour M; Ghiorzo P; Palmer JM; Bianchi Scarrà G; Hayward NK; Hansson J
J Invest Dermatol; 2010 Feb; 130(2):618-20. PubMed ID: 19759551
[No Abstract] [Full Text] [Related]
4. [Molecular biology of familial cases of human melanoma].
Kit OI; Vodolazhsky DL; Timoshkina NN; Przhedetsky YV; Khokhlova OV
Vopr Onkol; 2015; 61(6):889-97. PubMed ID: 26995975
[TBL] [Abstract][Full Text] [Related]
5. [Genotypic hypervariability of melanoma: a therapeutic challenge].
Dalle S; Martin-Denavit T; Thomas L
Med Sci (Paris); 2006 Feb; 22(2):178-82. PubMed ID: 16457759
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT.
Daniotti M; Ferrari A; Frigerio S; Casieri P; Miselli F; Zucca E; Collini P; Della Torre G; Manoukian S; Peissel B; Bono A; Santinami M; Parmiani G; Rivoltini L; Pilotti S; Rodolfo M
J Invest Dermatol; 2009 Jul; 129(7):1759-68. PubMed ID: 19158841
[TBL] [Abstract][Full Text] [Related]
7. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor.
Curry JL; Falchook GS; Hwu WJ; Torres-Cabala CA; Duvic M; Tetzlaff MT; Prieto VG
Am J Dermatopathol; 2013 Feb; 35(1):125-8. PubMed ID: 22878367
[TBL] [Abstract][Full Text] [Related]
8. MicroRNAs in the pathogenesis of malignant melanoma.
Glud M; Gniadecki R
J Eur Acad Dermatol Venereol; 2013 Feb; 27(2):142-50. PubMed ID: 22621697
[TBL] [Abstract][Full Text] [Related]
9. Targeting x-linked inhibitor of apoptosis protein for melanoma therapy: the need for more homogeneous samples and the importance of cell lines.
Kwatra SG
J Invest Dermatol; 2011 Mar; 131(3):797. PubMed ID: 21068753
[No Abstract] [Full Text] [Related]
10. Angiogenesis in malignant melanoma.
Felcht M; Thomas M
J Dtsch Dermatol Ges; 2015 Feb; 13(2):125-36. PubMed ID: 25631130
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of tumour vascularization in cutaneous malignant melanoma: clinical implications.
Pastushenko I; Vermeulen PB; Van den Eynden GG; Rutten A; Carapeto FJ; Dirix LY; Van Laere S
Br J Dermatol; 2014 Aug; 171(2):220-33. PubMed ID: 24641095
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis in melanoma: an update with a focus on current targeted therapies.
Jour G; Ivan D; Aung PP
J Clin Pathol; 2016 Jun; 69(6):472-83. PubMed ID: 26865640
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis in melanoma.
Mahabeleshwar GH; Byzova TV
Semin Oncol; 2007 Dec; 34(6):555-65. PubMed ID: 18083379
[TBL] [Abstract][Full Text] [Related]
14. CDKN2A/CDK4 molecular study on 155 Italian subjects with familial and/or primary multiple melanoma.
Majore S; De Simone P; Crisi A; Eibenschutz L; Binni F; Antigoni I; De Bernardo C; Catricalà C; Grammatico P
Pigment Cell Melanoma Res; 2008 Apr; 21(2):209-11. PubMed ID: 18363633
[No Abstract] [Full Text] [Related]
15. Targeting NRAS in melanoma.
Kelleher FC; McArthur GA
Cancer J; 2012; 18(2):132-6. PubMed ID: 22453013
[TBL] [Abstract][Full Text] [Related]
16. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
Sharma A; Trivedi NR; Zimmerman MA; Tuveson DA; Smith CD; Robertson GP
Cancer Res; 2005 Mar; 65(6):2412-21. PubMed ID: 15781657
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms of melanoma.
Pickert A
Cutis; 2012 Mar; 89(3):E1-4. PubMed ID: 23961517
[No Abstract] [Full Text] [Related]
18. Urgent treatment of patients with metastatic melanoma using Braf inhibitors in the absence of Braf mutation status.
Nathan P; Sharma A; Lorigan P
Ann Oncol; 2013 Jun; 24(6):1712-3. PubMed ID: 23613475
[No Abstract] [Full Text] [Related]
19. Age does not appear to be a major indicator of CDKN2A or CDK4 mutations in melanoma patients in Spain.
Nagore E; Montoro A; Oltra S; Ledesma E; Botella-Estrada R; Millán JM; Oliver V; Fortea JM; Guillén C
Melanoma Res; 2005 Dec; 15(6):555-8. PubMed ID: 16314743
[No Abstract] [Full Text] [Related]
20. High- and low-penetrance cutaneous melanoma susceptibility genes.
Fargnoli MC; Argenziano G; Zalaudek I; Peris K
Expert Rev Anticancer Ther; 2006 May; 6(5):657-70. PubMed ID: 16759158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
